A composition in a water-in-oil-in-water (W/O/W) emulsion is disclosed. The composition comprises: (a) a continuous aqueous phase, comprising H.sub.2O; (b) an oil phase or an oil shell, dispersed in the continuous aqueous phase; and (c) a hydrophilic polymer, stabilizing an interface between the continuous aqueous phase and the oil phase or the oil shell to form the water-in-oil-in-water (W/O/W) emulsion. The oil phase or the oil shell comprises: (i) oil; (ii) an internal aqueous phase, dispersed within the oil or the oil shell; and (iii) a lipophilic sorbitan-polyester conjugate, stabilizing an interface between the oil and the inner aqueous phase to form a water-in-oil (W/O) emulsion. The lipophilic sorbitan-polyester conjugate comprises: (1) sorbitan; and (2) poly(lactide-co-ε-caprolactone) or polylactic acid (polylactide), conjugated to the sorbitan.

A composition in a water-in-oil-in-water (W/O/W) emulsion is disclosed. The composition comprises: (a) a continuous aqueous phase, comprising H.sub.2O; (b) an oil phase or an oil shell, dispersed in the continuous aqueous phase; and (c) a hydrophilic polymer, stabilizing an interface between the continuous aqueous phase and the oil phase or the oil shell to form the water-in-oil-in-water (W/O/W) emulsion. The oil phase or the oil shell comprises: (i) oil; (ii) an internal aqueous phase, dispersed within the oil or the oil shell; and (iii) a lipophilic sorbitan-polyester conjugate, stabilizing an interface between the oil and the inner aqueous phase to form a water-in-oil (W/O) emulsion. The lipophilic sorbitan-polyester conjugate comprises: (1) sorbitan; and (2) poly(lactide-co-ε-caprolactone) or polylactic acid (polylactide), conjugated to the sorbitan.

The present disclosure generally relates to petrolatum-based compositions for suspension of active ingredients and methods for forming stable suspensions of active ingredients in petrolatum, and more specifically to compositions of triple antibiotic cationic ointments. In particular, the present disclosure relates to a method for suspension of antibiotics and biocides in petrolatum at room temperature and a petrolatum-based composition having a stable suspension of active ingredients including antibiotics and biocides.

The present disclosure generally relates to petrolatum-based compositions for suspension of active ingredients and methods for forming stable suspensions of active ingredients in petrolatum, and more specifically to compositions of triple antibiotic cationic ointments. In particular, the present disclosure relates to a method for suspension of antibiotics and biocides in petrolatum at room temperature and a petrolatum-based composition having a stable suspension of active ingredients including antibiotics and biocides.

The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast. Preferably, topically administered roflumilast is used to treat fungal infections, fungal growth of and/or hypersensitivity to the fungi Malassezia spp. Patients may also be suffering from seborrheic dermatitis, dandruff, dupilumab facial redness, Tinea versicolor, Pityriasis versicolor, Tinea circinata, Tinea pedis, Tinea unguium, Tinea manus, Tinea cruris, Tinea corporis, Tinea faciei, Tinea capitis, and/or Tinea incognito. Topically administered roflumilast is a quick and effective antifungal agent and presents a viable alternative to current antifungal treatments.

The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast. Preferably, topically administered roflumilast is used to treat fungal infections, fungal growth of and/or hypersensitivity to the fungi Malassezia spp. Patients may also be suffering from seborrheic dermatitis, dandruff, dupilumab facial redness, Tinea versicolor, Pityriasis versicolor, Tinea circinata, Tinea pedis, Tinea unguium, Tinea manus, Tinea cruris, Tinea corporis, Tinea faciei, Tinea capitis, and/or Tinea incognito. Topically administered roflumilast is a quick and effective antifungal agent and presents a viable alternative to current antifungal treatments.

The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of fingolimod.

A method for treating influenza is described. The disclosed method generally involves administering an effective amount of a compound, for example baloxavir marboxil, to a subject having influenza, where the compound is administered initially at least about 48 hours after an onset of influenza. Generally, the effective amount is sufficient to alleviate a symptom of influenza in the subject as compared to a symptom that the subject has when the compound is first administered to the subject.

Provided herein are methods and compositions for the delivery of at least two active, therapeutic, or pharmaceutical agents in an oil-in-water emulsion, wherein at least one agent is delivered in the hydrophobic phase of the emulsion and at least one agent is delivered in the aqueous phase of the emulsion.

Disclosed here are pharmaceutical compositions of the compound of Formula (I) (LM030) suitable for topical administration. The compound can be in solubilized form, formulated with a solubilizing agent and one or more pharmaceutically acceptable excipients.